Key result
Elevated IL-6 over 29 pg/mL linked to higher mortality in acute heart failure.
Why the study?
The relationship between interleukin-6 (IL-6) levels and mortality based on heart failure phenotype in acute heart failure remained unclear.
Does elevated IL-6 predict mortality differently in acute heart failure patients with HFrEF versus HFpEF?
Observational (n=371)
No
Does elevated IL-6 predict mortality differently in acute heart failure patients with HFrEF versus HFpEF?
Elevated IL-6 levels predict higher all-cause mortality in acute heart failure, with early mortality risk in HFpEF and later mortality risk in HFrEF.
Answers are grounded in this paper and cite their sources.
IL-6 should not guide AHF risk stratification by phenotype yet; leaves open differential mortality associations in HFrEF versus HFpEF.
Interleukin-6 (IL-6) plays a role in acute heart failure (AHF) and can predict death and re-hospitalization. However, the relationship between IL-6 levels and mortality, based on heart failure phenotype, remains unclear. This study aimed to clarify the association between IL-6 levels and mortality in patients with AHF with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). A retrospective observational study was conducted on 371 AHF cases admitted to our institution. Patients were categorized into two groups based on IL-6 levels using Receiver Operating Characteristic (ROC) curve analysis: those with IL-6 below 29.0 pg/mL (N = 239) and those above 29.0 pg/mL (N = 132). Mortality rates were assessed for both HFrEF and HFpEF patients to determine the differential impact of IL-6. The average age was 71 years, with 60% male. Over a median follow-up of 222 days, 53 patients (14.8%) died. Kaplan–Meier analysis revealed a significantly higher mortality rate in patients with IL-6 levels above 29.0 pg/mL ( P < 0.001). Elevated IL-6 levels were associated with increased mortality in both categories of left ventricular ejection fraction. In particular, among patients with HFrEF, those with elevated IL-6 levels exhibited a higher risk of death after 30 days ( P = 0.017), while HFpEF patients with elevated IL-6 levels had a higher risk of death within 30 days ( P = 0.002). Elevated IL-6 levels predicted higher all-cause mortality in both HFrEF and HFpEF patients. The effect of elevated IL-6 on mortality varies between short-term and long-term implications for HFrEF and HFpEF.
No takes yet. Share an insight, caveat, or question.
Kishihara et al. (2026) conducted an observational in Acute heart failure (n=371). Elevated Interleukin-6 (IL-6) levels (> 29.0 pg/mL) vs. IL-6 levels < 29.0 pg/mL was evaluated on Mortality (p=<0.001). Elevated IL-6 levels were associated with higher mortality in patients with acute heart failure compared to lower levels.
Synapse has enriched 10 related papers. Consider them for comparative context: